206 related articles for article (PubMed ID: 18830058)
1. Successful treatment of lupoid cutaneous leishmaniasis with glucantime and topical trichloroacetic acid (a case report).
Nilforoushzadeh MA; Sadeghian G; Jaffary F; Ziaei H; Shirani-Bidabad L; Mahzoni P
Korean J Parasitol; 2008 Sep; 46(3):175-7. PubMed ID: 18830058
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol.
Momeni AZ; Aminjavaheri M
Eur J Dermatol; 2003; 13(1):40-3. PubMed ID: 12609780
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous lupoid leishmaniasis: a case report.
Ferahbaş A; Mistik S; Utaş S; Yaman O; Canoz O; Doganay M; Aşçioglu O
Cutis; 2006 Jan; 77(1):25-8; quiz 37-8. PubMed ID: 16475491
[TBL] [Abstract][Full Text] [Related]
4. Clinical follow-up examination after treatment of canine leishmaniasis.
Moritz A; Steuber S; Greiner M
Tokai J Exp Clin Med; 1998 Dec; 23(6):279-83. PubMed ID: 10622623
[TBL] [Abstract][Full Text] [Related]
5. Comparison of lesion improvement in lupoid leishmaniasis patients with two treatment approaches: trichloroacetic Acid and intralesional meglumine antimoniate.
Banihashemi M; Yazdanpanah MJ; Amirsolymani H; Yousefzadeh H
J Cutan Med Surg; 2015; 19(1):35-9. PubMed ID: 25775661
[TBL] [Abstract][Full Text] [Related]
6. Allopurinol in the treatment of American cutaneous leishmaniasis.
Martinez S; Marr JJ
N Engl J Med; 1992 Mar; 326(11):741-4. PubMed ID: 1738379
[TBL] [Abstract][Full Text] [Related]
7. [N-methyl glucamine antimoniate or Glucantime].
Rapp C; Simon F; Dordain ML
Med Trop (Mars); 2000; 60(4):342-3. PubMed ID: 11436584
[No Abstract] [Full Text] [Related]
8. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
Layegh P; Yazdanpanah MJ; Vosugh EM; Pezeshkpoor F; Shakeri MT; Moghiman T
Am J Trop Med Hyg; 2007 Jul; 77(1):99-101. PubMed ID: 17620637
[TBL] [Abstract][Full Text] [Related]
9. PCR follow-up examination after treatment of canine leishmaniosis (CaL).
Steuber S; Moritz A; Schirrmann I; Greiner M
Tokai J Exp Clin Med; 1998 Dec; 23(6):285-92. PubMed ID: 10622624
[TBL] [Abstract][Full Text] [Related]
10. Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults.
Layegh P; Rahsepar S; Rahsepar AA
Am J Trop Med Hyg; 2011 Apr; 84(4):539-42. PubMed ID: 21460006
[TBL] [Abstract][Full Text] [Related]
11. Effective meglumine antimoniate intralesional therapy for Chiclero's ulcer refractory to systemic liposomal amphotericin B.
Spinicci M; Zammarchi L; Gramiccia M; Di Muccio T; Bartolozzi D; Corsi P; Trotta M; Bartoloni A
J Travel Med; 2021 Aug; 28(6):. PubMed ID: 32918547
[No Abstract] [Full Text] [Related]
12. Cutaneous leishmaniasis "chiclero's ulcer" in subtropical Ecuador.
Calvopiña M; Martinez L; Hashiguchi Y
Am J Trop Med Hyg; 2013 Aug; 89(2):195-196. PubMed ID: 23926136
[TBL] [Abstract][Full Text] [Related]
13. [A Pediatric case of lupoid leishmaniasis diagnosed by PCR].
Paradisi M; Grosso MG; Angelo C; Gradoni L; Ludovisi A; N'Doni F; Puddu P
Minerva Pediatr; 2001 Feb; 53(1):33-7. PubMed ID: 11419394
[TBL] [Abstract][Full Text] [Related]
14. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report.
Pimentel MI; Baptista C; Rubin EF; Vasconcellos Ede C; Lyra MR; Salgueiro Mde M; Saheki MN; Rosalino CM; Madeira Mde F; Silva AF; Confort EM; Schubach Ade O
Rev Soc Bras Med Trop; 2011; 44(2):254-6. PubMed ID: 21552747
[TBL] [Abstract][Full Text] [Related]
15. [Clinical, epidemiological and evolutionary aspects in 157 cases of cutaneous leishmaniasis in Morocco].
Hjira N; Frikh R; Marcil T; Lamsyah H; Oumakhir S; Baba N; Boui M
Pan Afr Med J; 2014; 17():272. PubMed ID: 25309671
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate.
Perez-Franco JE; Cruz-Barrera ML; Robayo ML; Lopez MC; Daza CD; Bedoya A; Mariño ML; Saavedra CH; Echeverry MC
PLoS Negl Trop Dis; 2016 May; 10(5):e0004739. PubMed ID: 27243811
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity to Glucantime of Leishmania viannia isolated from patients prior to treatment.
Robledo SM; Valencia AZ; Saravia NG
J Parasitol; 1999 Apr; 85(2):360-6. PubMed ID: 10219320
[TBL] [Abstract][Full Text] [Related]
18. Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy.
Shamsi Meymandi S; Javadi A; Dabiri S; Shamsi Meymandi M; Nadji M
Arch Iran Med; 2011 Jul; 14(4):238-43. PubMed ID: 21726098
[TBL] [Abstract][Full Text] [Related]
19. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
Andersen EM; Cruz-Saldarriaga M; Llanos-Cuentas A; Luz-Cjuno M; Echevarria J; Miranda-Verastegui C; Colina O; Berman JD
Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547
[TBL] [Abstract][Full Text] [Related]
20. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
